TEANECK, N.J. / Jul 31, 2023 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2023 financial results on Wednesday, August 30, 2023, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 31, 2023, at 9:00 AM Eastern Time.
Interested parties are invited to listen to the conference call and view the presentation slides by visiting http://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884
A replay of the webcast will be available approximately two hours after the conclusion of the live event. To access the webcast recording, visit https://investors.pahc.com.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com.
Our filings with the Securities and Exchange Commission are available online at www.sec.gov, www.pahc.com or on request from the company.
| Last Trade: | US$23.50 |
| Daily Change: | 0.65 2.84 |
| Daily Volume: | 276,784 |
| Market Cap: | US$477.990M |
August 28, 2024 February 06, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
